Command Palette

Search for a command to run...

Clinical Trials · NCT06515418

Efficacy and Safety of Oral Azelaprag Plus Once Weekly Tirzepatide Compared with Tirzepatide Alone in Participants with Obesity Aged 55 Years and Over

TerminatedPhase 2Tirzepatide (Prohibited)
Phase
Phase 2
Recruitment status
Terminated
Sponsor
BioAge Labs, Inc.
Enrollment
204
Start date
Jun 2024
Locations
14 sites, United States
Primary endpoint
Mean Percent Change in Body Weight (Azelaprag Once per Day)
View Tirzepatide compound reference